[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Zerbib et al., 2021 - Google Patents

VDAC1 silencing in cancer cells leads to metabolic reprogramming that modulates tumor microenvironment

Zerbib et al., 2021

View HTML
Document ID
5533632438551456984
Author
Zerbib E
Arif T
Shteinfer-Kuzmine A
Chalifa-Caspi V
Shoshan-Barmatz V
Publication year
Publication venue
Cancers

External Links

Snippet

Simple Summary Tumors are comprised of proliferating cancer cells, and their microenvironment consists of the extracellular matrix, blood vessels, and a variety of tissue cells. The tumor microenvironment functions in cell growth, proliferation, migration, immunity …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Seker-Polat et al. Tumor cell infiltration into the brain in glioblastoma: from mechanisms to clinical perspectives
Verigos et al. The histone demethylase LSD1/ΚDM1A mediates chemoresistance in breast cancer via regulation of a stem cell program
Zonneveld et al. Extracellular vesicles as transmitters of hypoxia tolerance in solid cancers
Chi et al. LncRNA RP11-79H23. 3 functions as a competing endogenous RNA to regulate PTEN expression through sponging hsa-miR-107 in the development of bladder cancer
Zerbib et al. VDAC1 silencing in cancer cells leads to metabolic reprogramming that modulates tumor microenvironment
Ma et al. Extracellular vesicles secreted by glioma stem cells are involved in radiation resistance and glioma progression
Belvedere et al. miR-196a is able to restore the aggressive phenotype of annexin A1 knock-out in pancreatic cancer cells by CRISPR/Cas9 genome editing
Zhang et al. The miRNA-21-5p payload in exosomes from M2 macrophages drives tumor cell aggression via PTEN/Akt signaling in renal cell carcinoma
Wiechec et al. Cancer-associated fibroblasts modulate transcriptional signatures involved in proliferation, differentiation and metastasis in head and neck squamous cell carcinoma
Venkatesan et al. MDM2 overexpression modulates the angiogenesis-related gene expression profile of prostate cancer cells
Kovacheva et al. Conditional knockdown of osteopontin inhibits breast cancer skeletal metastasis
Qin et al. miR-224-5p contained in urinary extracellular vesicles regulates PD-L1 expression by inhibiting cyclin D1 in renal cell carcinoma cells
Luo et al. Circular RNA hsa_circ_0000190 facilitates the tumorigenesis and immune evasion by upregulating the expression of soluble PD-L1 in non-small-cell lung cancer
Kobayashi et al. Inhibition of UCH-L1 deubiquitinating activity with two forms of LDN-57444 has anti-invasive effects in metastatic carcinoma cells
Winter et al. Vimentin promotes the aggressiveness of triple negative breast cancer cells surviving chemotherapeutic treatment
Sheta et al. The polypeptide GALNT6 displays redundant functions upon suppression of its closest homolog GALNT3 in mediating aberrant O-glycosylation, associated with ovarian cancer progression
Tong et al. LncRNA HCP5-encoded protein regulates ferroptosis to promote the progression of triple-negative breast cancer
Tesauro et al. Different camptothecin sensitivities in subpopulations of colon cancer cells correlate with expression of different phospho-isoforms of topoisomerase i with different activities
Higa et al. Formin-like 1 (FMNL1) is associated with glioblastoma multiforme mesenchymal subtype and independently predicts poor prognosis
Giuntini et al. Inhibition of melanoma cell migration and invasion targeting the hypoxic tumor associated CAXII
Chiu et al. Lactotransferrin downregulation drives the metastatic progression in clear cell renal cell carcinoma
Yang et al. The potential role of cathepsin K in non-small cell lung cancer
Li et al. LncRNA PVT1 is a poor prognosticator and can be targeted by PVT1 antisense oligos in gastric adenocarcinoma
Pseftogas et al. The tumor suppressor CYLD inhibits mammary epithelial to mesenchymal transition by the coordinated inhibition of YAP/TAZ and TGFβ signaling
Cao et al. UCHL5 promotes proliferation and migration of bladder cancer cells by activating c-myc via AKT/mTOR signaling